Kenvue Sees Unusually High Options Volume (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE - Get Free Report) saw unusually large options trading on Friday. Traders purchased 58,704 put options on the stock. This is an increase of 131% compared to the average volume of 25,459 put options.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KVUE. Cambridge Investment Research Advisors Inc. grew its position in Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after purchasing an additional 4,034 shares during the last quarter. Starboard Value LP purchased a new stake in Kenvue during the 4th quarter worth approximately $467,864,000. TrueMark Investments LLC grew its position in Kenvue by 9.3% during the 4th quarter. TrueMark Investments LLC now owns 190,595 shares of the company's stock worth $4,069,000 after purchasing an additional 16,161 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in Kenvue during the 1st quarter worth approximately $413,000. Finally, Cooper Investors PTY Ltd. boosted its holdings in shares of Kenvue by 39.7% in the 1st quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock valued at $20,577,000 after acquiring an additional 244,043 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

Shares of NYSE:KVUE traded up $0.15 on Friday, reaching $22.00. The company's stock had a trading volume of 12,727,162 shares, compared to its average volume of 16,312,363. Kenvue has a 52-week low of $17.85 and a 52-week high of $25.17. The company has a market cap of $42.21 billion, a P/E ratio of 40.00, a PEG ratio of 3.43 and a beta of 0.83. The company has a 50-day simple moving average of $22.15 and a 200 day simple moving average of $22.30. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the previous year, the company earned $0.28 EPS. The firm's revenue for the quarter was down 3.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on KVUE. Bank of America cut their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Redburn Atlantic started coverage on shares of Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. Barclays lowered their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a report on Tuesday, July 15th. Finally, UBS Group cut their target price on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $24.71.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.